KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 126 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,952,900 | +74.8% | 170,000 | +41.7% | 0.04% | +50.0% |
| Q2 2023 | $1,689,600 | +20.8% | 120,000 | -7.7% | 0.03% | +7.1% |
| Q1 2023 | $1,398,800 | +33.4% | 130,000 | +85.7% | 0.03% | +75.0% |
| Q4 2022 | $1,048,600 | +35.8% | 70,000 | +16.7% | 0.02% | +60.0% |
| Q3 2022 | $772,000 | -34.2% | 60,000 | -50.5% | 0.01% | -37.5% |
| Q2 2022 | $1,173,000 | -57.2% | 121,184 | -56.0% | 0.02% | -52.9% |
| Q1 2022 | $2,739,000 | +53.9% | 275,623 | +82.2% | 0.03% | +70.0% |
| Q4 2021 | $1,780,000 | +101.6% | 151,265 | +95.2% | 0.02% | +100.0% |
| Q3 2021 | $883,000 | -12.1% | 77,500 | +7.6% | 0.01% | -16.7% |
| Q2 2021 | $1,004,000 | -64.9% | 72,000 | -53.3% | 0.01% | -80.6% |
| Q1 2021 | $2,859,000 | +169.7% | 154,340 | +157.2% | 0.06% | +158.3% |
| Q4 2020 | $1,060,000 | +1.7% | 60,000 | -11.8% | 0.02% | -4.0% |
| Q3 2020 | $1,042,000 | – | 68,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |